In order to implement the work requirements of Beijing action plan for accelerating collaborative innovation in medicine and health (2021-2023), continue to promote the innovation of pharmaceutical base, technological innovation of drug and device industry, realize the wide application of new technologies and products, and promote the listed products of enterprises to enter the hospital, the management Committee of Daxing biological medicine base cooperates with Daxing District Health Commission, Daxing District Medical Insurance Bureau Daxing District Industry Promotion Center and Daxing District Finance Bureau held the "docking meeting of innovative products of Daxing biomedical industry base into the hospital" at China Pharmaceutical Valley Science and innovation center on the morning of March 8. Yu Jian, CEO of MIOK, was invited to attend the meeting.
CEO Yu Ting of MIOK (one on the left of the first row)
At the beginning of the meeting, Yu Jian, as a representative of enterprises, took the stage to speak. He said that China's biomedical industry is still in the catch-up stage and faces many obstacles that need to be broken through. On the one hand, the speed of registration and approval of innovative products needs to be improved; on the other hand. The admission process of registered products needs to be optimized, which is already a bottleneck problem for pharmaceutical enterprises. The "zero distance" communication between enterprises and hospitals has played a positive role in promoting the market-oriented application of innovative products in the park. Therefore, on behalf of other brother enterprises, I would like to express my heartfelt thanks to the government for setting up a docking and exchange platform between government and enterprises, institutes and enterprises to solve the "last mile" problem for enterprises.
Yu Ting, CEO of MIOK, spoke on the stage
Subsequently, he made a direct and objective all-round display of the application field, outstanding advantages, action principle and early clinical application data of MIOK innovative product "artificial cornea".
Michaelis artificial cornea was registered in 12 copies in 2021 and put into clinical use. As the world's first non-tissue material artificial cornea, Michaelis artificial cornea has perfectly realized the replacement of donor cornea, and provides a new way for the clinical treatment of patients with contraindications to traditional corneal transplantation: Patients with binocular corneal blindness who are difficult to succeed in corneal transplantation, including the vascularization of severe keratoconjunctival scar caused by corneal membrane transplantation failure, chemical injury, thermal burn, explosion injury, etc, Eyelid atresia, serious autoimmune diseases (such as Stevens Johnson syndrome and cicatricial pemphigoid) and corneal blindness caused by end-stage dry eye can be restored by Michaelis artificial cornea. This situation shows that the current situation of scarce corneal donors in China can be alleviated, the field of international ophthalmology is no longer blank, and the restoration of vision of 4 million corneal blindness patients in China is just around the corner!
Microkpro
This meeting has strengthened the relationship between MIOK and drug production enterprises, business enterprises and hospitals, and will play a positive role in promoting the development of our company. MIOK will also continue to adhere to the concept of "innovation and development", focus on the innovative resource advantages of the medical and health industry in Daxing District, shape the core competitiveness, support the industrial chain with the innovation chain, and actively build an artificial cornea brand trusted by blind patients with new technologies, new products and new models.